Medical isotope company Shine Technologies and Telix Pharmaceuticals have signed an agreement covering the supply of lutetium-177 (Lu-177) to Telix for clinical development of potential new therapeutics to treat prostate and kidney cancer.
Under the clinical supply agreement, Shine will immediately commence supply of n.c.a. Lu-177 for use in clinical trials of Telix's therapeutic candidates TLX591 (Lu-177 rosopatamab for advanced prostate cancer) and TLX250 (Lu-177 girentuximab for kidney cancer), according to Shine.
Isotope production will take place at Shine's facility in Fitchburg, WI. Shine is currently expanding, with a new facility under construction in Janesville, WI, near its headquarters, and a facility in the design phase in Veendam, the Netherlands.
